Titre : | Opioid use disorder. Treatment with injectable and implantable buprenorphine. Report to Congressional Committees |
Auteurs : | United States Government Accountability Office |
Type de document : | Rapport |
Mention d'édition : | GAO-20-617 |
Editeur : | Washington, DC : U.S. Government Accountability Office (GAO), 2020 |
Format : | 21 p. |
Note générale : |
Voir aussi :
Rubin R. Buprenorphine implants, injections are underused. Journal of the American Medical Association, 2020, Vol. 324, n° 12, p. 1128. https://doi.org/10.1001/jama.2020.17587 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus géographique ETATS-UNISThésaurus mots-clés OPIOIDES ; TRAITEMENT DE MAINTENANCE ; BUPRENORPHINE ; INJECTION ; VOIE D'ADMINISTRATION ; VOIE SOUSCUTANEE ; VOIE INTRAMUSCULAIRE ; PRESCRIPTION MEDICALE ; PHARMACIE |
Résumé : |
Treatment for opioid use disorder may involve buprenorphine - a drug that can reduce or eliminate withdrawal symptoms and prevent relapse.
We reviewed the use of long-acting injectable and implantable forms of buprenorphine for opioid use disorder. These forms release the drug over 1- or 6-month periods respectively. Providers issued about 7,250 prescriptions for injectable or implantable buprenorphine in FY 2019. Providers and pharmacy representatives said there is a low risk of these forms of the drug being diverted to the illegal marketplace. |
Domaine : | Autres substances / Other substances ; Drogues illicites / Illicit drugs |
Affiliation : | Washington, DC, USA |
Lien : | https://www.gao.gov/products/GAO-20-617 |
Exemplaires
Disponibilité |
---|
aucun exemplaire |
Accueil